Status:
COMPLETED
Study in Patients With Asthma
Lead Sponsor:
Dey
Conditions:
Asthma
Eligibility:
All Genders
12-70 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine which dose of the investigational drug is safest and most effective compared to the control drug.
Eligibility Criteria
Inclusion
- Require regular use of an inhaled Beta-2-selective adrenergic agent
Exclusion
- Active acute or chronic disorders of the respiratory system within one month prior to screening
- Smoking history within the past 12 months or greater than a lifetime 10 pack-year smoking history
- Recent surgical interventions such as lung lobectomy or resection (\< one year), or cardiothoracic interventions
- Life-threatening systemic and debilitating diseases.
Key Trial Info
Start Date :
July 1 2002
Trial Type :
INTERVENTIONAL
End Date :
December 1 2005
Estimated Enrollment :
32 Patients enrolled
Trial Details
Trial ID
NCT00215358
Start Date
July 1 2002
End Date
December 1 2005
Last Update
November 11 2010
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Denver, Colorado, United States, 80206
2
Research Site
Medford, Oregon, United States, 97504